OptimizeRx Invited to Host Plenary Sessions at Digital Pharma East on September 17-20, 2019
September 10 2019 - 1:00PM
OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital
health messaging for the pharmaceutical industry, will host two
plenary sessions at the 13th Annual Digital Pharma East conference
being held at the Pennsylvania Convention Center in Philadelphia on
September 17-20, 2019.
Bringing together more than 1,000 participants, this conference
will feature latest case studies and senior-level discussions with
pharma companies, health systems, physicians, health-tech
companies, startups and non-traditional healthcare companies
involved in digital health.
The first plenary session, “Success in Today’s Evolving Pharma
Marketing Landscape,” will be hosted by Steve Silvestro, chief
commercial officer of OptimizeRx, at 11:00 a.m. Eastern time on
September 17.
In this session, Silvestro will be joined by Dr. Harry Greenspun
of Guidehouse, Angelo Campano of Ogilvy, and Kai Bode of Merck.
They will discuss the imperatives of ‘going digital’ and how this
can affect organizations across the care spectrum. They will also
discuss the evolution of pharma marketing, and how all
stakeholders—pharma, providers and patients—are looking to digital
innovations to lower costs and improve outcomes.
The second plenary session, “Innovation and Communication in
Today’s Digitally-Charged Pharma Landscape,” will be hosted by
Miriam Paramore, president of OptimizeRx, at 3:30 p.m. Eastern time
on September 18.
In this session, Paramore will facilitate a panel discussion
that includes Dr. Harry Greenspun of Guidehouse and Dr. Jack Pinney
of MidMichigan Health. The panel will provide insight and direction
on the marketing options currently available to the pharma
industry, and what is needed to encourage positive change that
results in greater financial returns and improved outcomes.
The panel will also discuss how pharma and providers can
improve communications and work better together as a connected team
to improve care for patients.
OptimizeRx’s VP of marketing and communications, Rebecca
Whitney, has also been appointed to the 2019 Digital Pharma East
advisory board.
About Digital Pharma EastDigital Pharma East is
the leading marketing conference globally for life science
professionals looking to learn, network and be inspired. For more
information, visit www.digitalpharmaseries.com/east.
About OptimizeRx
OptimizeRx® (NASDAQ: OPRX), a digital health company, connects
pharmaceutical companies to patients and providers, offering
greater affordability, adherence and brand awareness at the
point-of-care. As the nation’s largest point-of-prescribe
promotional platform for the pharmaceutical
industry, OptimizeRx provides a direct channel for pharma
companies to communicate with healthcare providers right within
their workflow and also directly to patients.
The cloud-based solution supports patient adherence to
medications and better healthcare outcomes with real-time access to
financial assistance, prior authorization, education and critical
clinical information. OptimizeRx provides more than half
of the ambulatory patient market with access to these benefits
through leading EHR platforms like Allscripts, Amazing Charts and
Quest, and directly via its mobile communications
platform.
For more information, follow the company
on Twitter, LinkedIn or
visit www.optimizerx.com.
Important Cautions Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the definition of Section 27A of the Securities Act of 1933, as
amended, and such as in section 21E of the Securities Act of 1934,
as amended. These forward-looking statements should not be used to
make an investment decision. The words 'estimate,' 'possible' and
'seeking' and similar expressions identify forward-looking
statements, which speak only as to the date the statement was made.
The company undertakes no obligation to publicly update or revise
any forward-looking statements, whether because of new information,
future events, or otherwise. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted, or quantified. Future events and actual results could
differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and
uncertainties to which forward-looking statements are subject
include, but are not limited to, the effect of government
regulation, competition and other material risks.
OptimizeRx Contact Doug
Baker, CFO Tel (248) 651-6568
x807 dbaker@optimizerx.com
Media Relations Contact Nicole
Brooks, Innsena Communications Tel (860) 800-2344 nicolebrooks@innsena.com
Investor Relations Contact Ron Both,
CMA Tel (949) 432-7557 oprx@cma.team
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024